155 related articles for article (PubMed ID: 21119366)
21. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
22. Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary?
Kajiyama H; Shibata K; Suzuki S; Ino K; Yamamoto E; Mizuno K; Sakakibara K; Matsuzawa K; Takeda A; Kinoshita Y; Kawai M; Nagasaka T; Nawa A; Kikkawa F
Gynecol Oncol; 2008 Dec; 111(3):523-6. PubMed ID: 18538833
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
[TBL] [Abstract][Full Text] [Related]
24. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy.
Recio FO; Piver MS; Hempling RE; Driscoll DL
Cancer; 1996 Nov; 78(10):2157-63. PubMed ID: 8918409
[TBL] [Abstract][Full Text] [Related]
25. Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma.
Tsubamoto H; Sonoda T; Yamasaki M; Inoue K
Anticancer Res; 2014 Apr; 34(4):2007-14. PubMed ID: 24692739
[TBL] [Abstract][Full Text] [Related]
26. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.
Molckovsky A; Vijay SM; Hopman WM; Bryson P; Jeffrey JF; Biagi JJ
Int J Gynecol Cancer; 2008; 18(1):8-13. PubMed ID: 17511802
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
[TBL] [Abstract][Full Text] [Related]
28. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.
Goff BA; Sainz de la Cuesta R; Muntz HG; Fleischhacker D; Ek M; Rice LW; Nikrui N; Tamimi HK; Cain JM; Greer BE; Fuller AF
Gynecol Oncol; 1996 Mar; 60(3):412-7. PubMed ID: 8774649
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma.
Ho CM; Chien TY; Shih BY; Huang SH
Gynecol Oncol; 2003 Mar; 88(3):394-9. PubMed ID: 12648592
[TBL] [Abstract][Full Text] [Related]
30. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
[TBL] [Abstract][Full Text] [Related]
31. Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer.
Lee JY; Kim TH; Suh DH; Kim JW; Kim HS; Chung HH; Park NH; Song YS; Kang SB
Eur J Surg Oncol; 2015 Apr; 41(4):585-91. PubMed ID: 25624160
[TBL] [Abstract][Full Text] [Related]
32. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
33. Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy.
Kunito S; Takakura S; Nagata C; Saito M; Yanaihara N; Yamada K; Okamoto A; Sasaki H; Ochiai K; Tanaka T
J Obstet Gynaecol Res; 2012 Dec; 38(12):1367-75. PubMed ID: 22639843
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
Ma SK; Zhang HT; Wu LY; Liu LY
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
[TBL] [Abstract][Full Text] [Related]
35. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sugiyama T; Kikuchi Y; Suzuki M; Terakawa N
Obstet Gynecol; 2002 Aug; 100(2):281-7. PubMed ID: 12151151
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.
Utsunomiya H; Akahira J; Tanno S; Moriya T; Toyoshima M; Niikura H; Ito K; Morimura Y; Watanabe Y; Yaegashi N
Int J Gynecol Cancer; 2006; 16(1):52-6. PubMed ID: 16445610
[TBL] [Abstract][Full Text] [Related]
37. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
38. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Crotzer DR; Sun CC; Coleman RL; Wolf JK; Levenback CF; Gershenson DM
Gynecol Oncol; 2007 May; 105(2):404-8. PubMed ID: 17292461
[TBL] [Abstract][Full Text] [Related]
39. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?
Rocconi RP; Sullivan P; Long B; Blaize M; Brown J; Arbuckle J; Bevis K; Estes JM; Reed E; Finan MA
Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832
[TBL] [Abstract][Full Text] [Related]
40. Impact of maintenance chemotherapy on disease-free survival in patients with stage Ic and II epithelial ovarian cancer.
Tanaka N; Matsui H; Nagai Y; Suzuka K; Seki K; Sekiya S
Eur J Gynaecol Oncol; 2002; 23(4):281-6. PubMed ID: 12214723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
